Dompé
19 articles about Dompé
-
Dompé farmaceutici Appoints Shannon K. Sullivan as Chief Commercial Officer Biotech
10/10/2023
Dompé today announced the appointment of Shannon K. Sullivan as Chief Commercial Officer (CCO), effective immediately.
-
Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease
2/9/2022
Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3 clinical trial to evaluate the efficacy and safety of cenegermin.
-
COVID-19 - Brazilian Health Regulatory Agency (ANVISA) authorizes Dompé's REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients
9/2/2020
10 Brazilian centers in São Paulo, Brasilia, Presidente Prudente, Sao José do Rio Preto, Varginha, Salvador de Bahia, Criciùma
-
Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting From Dompe Research For The Treatment Of Moderate To Severe Neurotrophic Keratitis Is Made In Italy
7/21/2017
-
Dompe Receives Positive CHMP Opinion In Europe For Oxervate (Cenegermin Eye Drops) For The Treatment Of Adult Patients With Moderate Or Severe Neurotrophic Keratitis
5/23/2017
-
Neurotrophic Keratitis: EMA Validates The Marketing Authorisation Application For Cenegermin Eye Drops (Oxervate) Submitted By Dompe
12/12/2016
-
Dompe Release: Research Presented At The San Antonio Breast Cancer Symposium Intended To Strike At The Heart Of Cancer Stem Cells
12/10/2015
-
Dry Eye Disease: An International Symposium By Dompé Focuses On New Research Addressing Unmet Patient Needs
9/4/2015
-
Dompe Offers A New "Window" On The World Of Scientific Research, With The http://Www.Dompetrials.Com Website, Dedicated To Clinical Trials
12/17/2014
-
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis
7/23/2014
-
Pharmaceutical Company Dompe Launches REP0112, a Trial to Assess the Efficacy and Safety of Reparixin in Autologous Islet Cell Transplantation
9/26/2013
-
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa
9/11/2013
-
Dompe Announces Innovative Treatment in the Fight Against Type 1 Diabetes: Pancreatic Islet Cell Transplantation, a Hope That Has Already Come True
7/11/2013
-
Dompe Announces the European Medicines Agency Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa
7/1/2013
-
Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis
2/14/2013
-
Dompé: The First International Clinical Ophthalmological Trial Concerning Treatment of Neurotrophic Keratitis (NK), an Ocular Pathology With No Cure, Takes Place in Italy
9/7/2012
-
AAA Acquires Rights to Oncology Antibody Treatment Fabovar from Dompe
8/1/2011
-
Dyax Corp. Enters into an Exclusive Negotiation Period with Dompe for European License to DX-88 in Angioedema Indications
7/15/2008
-
Protox Therapeutics Inc. Announces Manufacturing Agreement with Dompe for PRX321
7/17/2007